PDFE-2304 not checked

PDFE Pharma Innovations FZCO

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.”In the company’s words, NCT07011485 on ClinicalTrials.gov
Tested for
Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)
Main trialPhase 2
“This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).”In the company’s words, NCT07011485 on ClinicalTrials.gov

Other drugs for Alopecia, Androgenetic

All 36 drugs for Alopecia, Androgenetic

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 14 Aug 2025 A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow PDFE-2304

Following is part of Solo: you see every change to PDFE-2304 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in